- Home
- ENTA vs HKD Comparison
ENTA vs HKD Comparison
Compare ENTA & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTA | HKD |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 446.3M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ENTA | HKD |
|---|---|---|
| Price | $12.85 | $1.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | ★ 283.1K | 244.1K |
| Earning Date | 02-09-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $65,324,000.00 | ★ $87,436,000.00 |
| Revenue This Year | $0.99 | N/A |
| Revenue Next Year | $0.19 | N/A |
| P/E Ratio | ★ N/A | $12.54 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.09 | $1.26 |
| 52 Week High | $17.15 | $5.47 |
Technical Indicators
Market Signals| Indicator | ENTA | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 52.91 |
| Support Level | $12.09 | $1.36 |
| Resistance Level | $13.98 | $1.45 |
| Average True Range (ATR) | 0.73 | 0.05 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 19.01 | 93.33 |
Price Performance
Historical ComparisonAbout ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.